Who is sponsoring NCT03831230?

NCT03831230 is sponsored by Centre Francois Baclesse.

What drugs are being tested in NCT03831230?

Interventions in NCT03831230: collection of blood, urine, tumor and ascite samples.

What condition does NCT03831230 study?

NCT03831230 studies Ovarian Cancer.

Is NCT03831230 still recruiting?

NCT03831230 is currently completed. Last updated 8 August 2025.

Last reviewed 2025-08-08 · How we verify

NCT03831230: OVAREX

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Constitution of ex Vivo Ovarian Tumor Models for the Validation of the Interest of Innovative Therapies and the Search for Tumor or Circulating Biomarkers Predictive of Treatment Response

Completed Last updated 8 August 2025

What this trial tests

trial testing collection of blood, urine, tumor and ascite samples in Ovarian Cancer in 250 participants. Completed in 27 February 2025.

Timeline

7 March 2019

Primary endpoint
27 February 2025

27 February 2025

Quick facts

Lead sponsor	Centre Francois Baclesse
Status	Completed
Study type	OBSERVATIONAL
Enrollment	250
Start date	7 March 2019
Primary completion	27 February 2025
Estimated completion	27 February 2025
Sites	1 location across France

Drugs / interventions tested

collection of blood, urine, tumor and ascite samples

Conditions studied

Ovarian Cancer — all drugs for Ovarian Cancer →

Sponsor

Centre Francois Baclesse — full company profile →

Who can join

18 and older, female only, with Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Development of ex vivo models of ovarian cancer, fallopian tubes or peritoneum.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Precision oncology using ex vivo technology: a step towards individualised cancer care?
Williams ST, Wells G, Conroy S, Gagg H, et al · · 2022 · cited 14× · PMID 36184897 · DOI 10.1017/erm.2022.32
The OVAREX study: Establishment of ex vivo ovarian cancer models to validate innovative therapies and to identify predictive biomarkers.
Thorel L, Divoux J, Lequesne J, Babin G, et al · · 2024 · cited 7× · PMID 38849726 · DOI 10.1186/s12885-024-12429-w
Long-term patient-derived ovarian cancer organoids closely recapitulate tumor of origin and clinical response.
Thorel L, Dolivet E, Morice PM, Florent R, et al · · 2025 · cited 3× · PMID 41057919 · DOI 10.1186/s13046-025-03537-x
Shaping the future one slice at a time: How 3D organotypic tumour slice models are driving drug discovery in ovarian cancer.
Edwards M, Caruana P, Escar M, Céspedes MV. · · 2026 · PMID 41351993 · DOI 10.1016/j.tranon.2025.102633
LncRNA <i>MYO16-AS1</i> and <i>MICAL2</i> axis sustains proliferation and migration in ovarian cancer cells and unveils a therapeutic vulnerability in patient-derived tumor organoids.
Ahmad M, Thorel L, Brotin E, Abeilard E, et al · · 2025 · PMID 40822859 · DOI 10.1016/j.ncrna.2025.07.005

Verify or expand the search:

Other recruiting trials for Ovarian Cancer

Currently open trials in the same condition.

NCT06412120 — Study Evaluating Safety, Tolerability, and Metabolism of Niraparib · Phase 4 · recruiting
NCT06930755 — Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer · Phase 1 · recruiting
NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
NCT07491081 — EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection · NA · recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other Centre Francois Baclesse trials

Trials by the same sponsor.

NCT06959810 — Impact of Adapted Aesthetic Onco in Patients With Upper Aerodigestive Tract Cancer During Their Management · NA · recruiting
NCT06792721 — MEASUREMENT OF CIRCULATING MUTATION BURDEN · recruiting
NCT06817161 — Benefit of Transcutaneous Auricular Vagus Nerve Stimulation in Improving Quality of Life in First Line Treatment of Ovar · Phase 3 · recruiting
NCT06612827 — Development of Tumor Organoids From Undifferentiated Primary Carcinomas to Guide Therapeutic Decisions · recruiting
NCT06798922 — Flap Sparing in Postoperative Radiotherapy of Oral Cavity Cancers · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03831230 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Francois Baclesse
Last refreshed: 8 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03831230.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing